Vienna, Austria-based Cato produces software that automates the creation and sharing of data aimed at reducing human error, standardizing practices, and streamlining workflow in the process of delivering drugs in both pharmacy and clinical settings. In essence, the software tells drug dispensers how and how much of a drug to distribute, with the aim of reducing medical errors. As such, the business would tend to enhance BD's prefillable drug delivery systems and related businesses. In a statement, BD Medical-Medical Surgical Systems President William A. Tozzi predicted the Cato acquisition would "help us accelerate BD's growth, especially in the pharmacy segment."
Specific financial terms of the acquisition were not disclosed, although BD did allow that the transaction will probably be "minimally dilutive" in fiscal 2013. In any case, the company confirmed that the Cato purchase will not affect the firm's earnings guidance for this year.
In BD's Feb. Q1 2013 earnings release, the company guided investors to expect 3.5% to 4% revenue growth this year, with diluted earnings per share from continuing operations probably coming in between $5.69 and $5.72, resulting in 6% to 6.5% earnings growth year over year.
Fool contributor Rich Smith has no position in any stocks mentioned. The Motley Fool recommends Becton Dickinson. Try any of our Foolish newsletter services free for 30 days. We Fools may not all hold the same opinions, but we all believe that considering a diverse range of insights makes us better investors. The Motley Fool has a disclosure policy.
More from The Motley Fool
Spirit Airlines Raises Guidance: Will 2018 Be Even Better?
Spirit Airlines is recovering quickly from a damaging fare war with United. If Spirit can keep up the momentum, 2018 could be a great year for shareholders.
1 Major Threat Oracle Investors Can't Afford to Ignore
Some competitors are trying to bridge the moat surrounding its database dominance.
Will Apple Inc.'s Battery Replacement Program Hurt iPhone Sales?
One analyst thinks so.